MedTrace Logo

Tear Proteins, Conjunctival Cells and Imaging Eyes in Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients

NCT02217137 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2015-11-18

No results posted yet for this study

Summary

Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) are chronic systemic autoimmune diseases that have been reported to affect the ocular surface of patients \[1,2\]. However, the nature of the disturbances of the ocular surface immunity and their relationship to systemic disease severity are poorly understood.

This study aims to profile the ocular surface inflammation of RA and SLE patients by a., analysing levels of tear cytokine, and b., investigating conjunctival cells, and c. clinical imaging for conjunctival redness and tear stability.

20 consecutive RA patients and 20 consecutive SLE patients will be recruited from the Singapore General Hospital Rheumatology clinic. 20 age matched controls for SLE and another 20 age matched controls for RA will be recruited.

All participants will undergo

1. Tear collection with Schirmer strips
2. EyePRIMTM (Opia Technologies) Impression Cytology Device for conjunctival sampling
3. Clinical ocular surface assessment with Oculus Keratograph 5M
4. Collection of blood via venipuncture (optional)
5. Retrieval of Clinical Information of participants

The association of cytokines in the tears with various cellular and immune markers, as well as clinical signs of inflammation and tear stability will be investigated. This will be useful for further longitudinal studies of treatment in autoimmmune disease patients.

Conditions

  • Dry Eye

Sponsors & Collaborators

  • Singapore National Eye Centre

    lead OTHER_GOV

Eligibility

Min Age
21 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02217137 on ClinicalTrials.gov